punterpk

SUNPHARMA CHECK

השכלה
punterpk מעודכן   
NSE:SUNPHARMA   SUN PHARMACEUTICAL
For the past several weeks, SUNPHARMA has been lodged inside a downward channel while NIFTY has tested new highs. Now within this channel it seems to have formed a highly bearish Head & Shoulders pattern whose height is measured at a mind boggling 245 points! I wonder what does the market know that we poor slobs are unaware of! Worth watching this stock's chart for education.
הערה:
Below 372 but Volume needs to catch up.
הערה:

As this hourly chart shows, any rise to 385 levels should be used to short it as the price is dipping below 372 although breakdown volume is not seen yet.
הערה:
The tussle between bulls & bears is on. The stock has turned quite volatile. Volumes are rising. Today is weekly expiry so this is expected. No entry in the stock at present.
הערה:
It's 10:50am and our stock has touched 384.50. High risk traders can enter shorts with a strict stop loss.
הערה:
11:45am After going below 380 it sprung back up to eat stop losses, touched 386.85. Rest of the day is going to be crucial whether bulls can maintain their lead. I doubt it.
הערה:
12:28am Touched 388.60. Bulls have turned vicious taking bears to the cleaners.
הערה:
On the back of FED's comment that they MAY consider cutting rates, global markets rallied, and so did Sunpharma to touch 392 level yesterday. But Daily volume was still average. On a weekly basis our analysis above still stands unless it breaks above 436-38 levels. It must be noted that brokerage houses like ICICIBANK, Sharekhan have a HOLD call with 460 as target (which is still well below the right shoulder top of 484 in H&S pattern.)
הערה:
Recent bullish push to 410 level notwithstanding, once again Sunpharma is dipping below 372 levels and easily breached recent low of 368. I still feel it's got downward bearish potential that remains untapped.
כתב ויתור

המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.